微生态制剂联合阿德福韦酯治疗慢性乙型肝炎肝硬化的疗效及对机体免疫功能的影响

摘要

目的：探讨微生态制剂联合阿德福韦酯治疗慢性乙型肝炎肝硬化患者的临床疗效及对机体免疫功能的影响。方法选择化龙镇社区卫生服务中心收治的104例慢性乙型肝炎肝硬化患者作为研究对象，随机分为观察组和对照组，每组52例。观察组患者采用微生态制剂双歧杆菌三联活菌胶囊联合阿德福韦酯口服治疗6个月，对照组给予阿德福韦酯口服治疗6个月。检测各项生物化学指标，主要包括血常规，HBV DNA定量、肝纤维化指标、ALT、AST、ALB以及TBil。结果治疗6周后，观察组有效率（88.46%）高于对照组（71.15%），差异有统计学意义（χ2=4.83，P =0.03）。治疗后，两组患者肝功能均显著改善，其中观察组的ALT、TBil和AST水平均低于对照组，ALB水平高于对照组，差异有统计学意义（t值分别为4.26、12.90、6.97、15.09，P值分别为0.04、0.004、0.02、0.00）。观察组CD4+、CD4+/CD8+、NK水平显著高于对照组，CD8+水平显著低于对照组，差异有统计学意义（t值分别为4.39、14.09、7.64和6.90，P值分别为0.04、0.01、0.014和0.03）。结论阿德福韦酯联合微生态制剂治疗慢性乙型肝炎肝硬化疗效优于单用阿德福韦酯治疗，且有改善患者免疫功能及肝功能等优点，能更好地提高治疗效果。%s: Objective To discuss the curative effects of probiotics combined with adefovir dipivoxil in treatment of patients with HBV-related cirrhosis and the effects on immune function.MethodsTotal of 104 cases of hepatitis B with liver cirrhosis were selected and randomly divided into observation group and control group, 52 cases in each group. Patients in observation group were given probiotics Biifd Triple Viable capsule combined with adefovir dipivoxil for 6 months orally, and patients in control group were only given adefovir dipivoxil for 6 months. The biochemical indicators, mainly including routine blood, HBV DNA levels, liver ifbrosis indicators, ALT, AST, ALB and TBil were detected.Results After 6 weeks’ treatment, the effective rate of the observation group (88.46%) was higher than that of the control group (71.15%), the difference was statistically signiifcant (χ2 = 4.83,P = 0.03). The liver functions of the two groups both improved signiifcantly, the ALT, AST and TBil levels of the observation group were lower than those of the control group, the ALB level was lower than that of the control group, and the differences were statistically signiifcant (t = 4.26, 12.90, 6.97, 15.09; P = 0.04, 0.004, 0.02, 0.00). The CD4+, CD4+/CD8+ and NK levels of the observation group were signiifcantly higher than those of the control group, and the CD8+ level was signiifcantly lower than that of the control group, and the differences were statistically signiifcant (t = 4.39, 14.09, 7.64, 6.90;P = 0.04, 0.01, 0.014, 0.03). ConclusionsThe curative effects of probiotics combined with adefovir dipivoxil in treatment of hepatitis B patients with liver cirrhosis is better than single use, which has the advantages of improving immune function and liver function, and can improve the treatment effect.